Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT‐based radiomics signature

Tumor mutation burden (TMB) is an important determinant and biomarker for response of targeted therapy and prognosis in patients with lung cancer. The present study aimed to determine whether radiomics signature could non‐invasively predict the TMB status and driver mutations in patients with resectable early stage lung adenocarcinoma (LUAD).

[1]  Lauren L. Ritterhouse,et al.  Tumor mutational burden , 2019, Cancer cytopathology.

[2]  J. Sicklick,et al.  Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors , 2018, JAMA oncology.

[3]  R. Govindan,et al.  Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Xiaodong Yang,et al.  Ground glass opacities: Imaging, pathology, and gene mutations , 2018, The Journal of thoracic and cardiovascular surgery.

[5]  Nikolaus Schultz,et al.  Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers , 2018, Clinical Cancer Research.

[6]  Chung-Kuan Wu,et al.  Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations. , 2018, Journal of Thoracic Oncology.

[7]  Arun Ahuja,et al.  Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer , 2018, Cancer cell.

[8]  Ning Wang,et al.  Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. , 2018, The Lancet. Global health.

[9]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[10]  K. Kristiansen,et al.  Comprehensive targeted super-deep next generation sequencing enhances differential diagnosis of solitary pulmonary nodules. , 2018, Journal of thoracic disease.

[11]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[13]  D. Beer,et al.  Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers. , 2017, Cancer research.

[14]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[15]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[16]  Chintan Parmar,et al.  Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non–Small Cell Lung Cancer , 2017, The Journal of Nuclear Medicine.

[17]  Marco Aiello,et al.  Radiogenomic Analysis of Oncological Data: A Technical Survey , 2017, International journal of molecular sciences.

[18]  Hugo J. W. L. Aerts,et al.  Radiomic‐Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  Samuel H. Hawkins,et al.  Predicting Malignant Nodules from Screening CT Scans , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  L. Schwartz,et al.  Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC , 2016, Scientific Reports.

[21]  Yanqi Huang,et al.  Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. , 2016, Radiology.

[22]  A. Nicholson,et al.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  Siân Jones,et al.  Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA , 2015, Nature Communications.

[24]  M. Li,et al.  Time Trends in Epidemiologic Characteristics and Imaging Features of Lung Adenocarcinoma: A Population Study of 21,113 Cases in China , 2015, PloS one.

[25]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[26]  Shota Yamamoto,et al.  ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. , 2014, Radiology.

[27]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[28]  S. Lam,et al.  Probability of cancer in pulmonary nodules detected on first screening CT. , 2013, The New England journal of medicine.

[29]  T. Woodruff,et al.  Associations between , 2020 .

[30]  Prateek Prasanna,et al.  Radiomics and radiogenomics in lung cancer: A review for the clinician. , 2018, Lung cancer.

[31]  P. Huang,et al.  Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study. , 2018, Radiology.

[32]  Massimo Bellomi,et al.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer , 2015, European Radiology.

[33]  Liquid Biopsies.  Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.

[34]  Paul J. Perry,et al.  A Review for the Clinician , 2002 .

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[36]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.